Literature DB >> 35465070

Emerging Treatment Strategies for Patients With Primary Biliary Cholangitis.

Martin Moehlen1.   

Abstract

Entities:  

Year:  2021        PMID： 35465070      PMCID： PMC9021176     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Authors:  Christophe Corpechot; Olivier Chazouillères; Alexandra Rousseau; Antonia Le Gruyer; François Habersetzer; Philippe Mathurin; Odile Goria; Pascal Potier; Anne Minello; Christine Silvain; Armand Abergel; Maryline Debette-Gratien; Dominique Larrey; Olivier Roux; Jean-Pierre Bronowicki; Jérôme Boursier; Victor de Ledinghen; Alexandra Heurgue-Berlot; Eric Nguyen-Khac; Fabien Zoulim; Isabelle Ollivier-Hourmand; Jean-Pierre Zarski; Gisèle Nkontchou; Sara Lemoinne; Lydie Humbert; Dominique Rainteau; Guillaume Lefèvre; Luc de Chaisemartin; Sylvie Chollet-Martin; Farid Gaouar; Farid-Hakeem Admane; Tabassome Simon; Raoul Poupon
Journal:  N Engl J Med       Date:  2018-06-07       Impact factor: 91.245

2.  Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.

Authors:  Andreas E Kremer; Marlyn J Mayo; Gideon Hirschfield; Cynthia Levy; Christopher L Bowlus; David E Jones; Alexandra Steinberg; Charles A McWherter; Yun-Jung Choi
Journal:  Liver Int       Date:  2021-08-26       Impact factor: 5.828

3.  Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Authors:  David Jones; Pol F Boudes; Mark G Swain; Christopher L Bowlus; Michael R Galambos; Bruce R Bacon; Yvonne Doerffel; Norman Gitlin; Stuart C Gordon; Joseph A Odin; David Sheridan; Markus-Alexander Wörns; Virginia Clark; Linsey Corless; Heinz Hartmann; Mark E Jonas; Andreas E Kremer; George F Mells; Peter Buggisch; Bradley L Freilich; Cynthia Levy; John M Vierling; David E Bernstein; Marek Hartleb; Ewa Janczewska; Fedja Rochling; Hemant Shah; Mitchell L Shiffman; John H Smith; Yun-Jung Choi; Alexandra Steinberg; Monika Varga; Harinder Chera; Robert Martin; Charles A McWherter; Gideon M Hirschfield
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-08-14

4.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

5.  A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.

Authors:  Jörn M Schattenberg; Albert Pares; Kris V Kowdley; Michael A Heneghan; Stephen Caldwell; Daniel Pratt; Alan Bonder; Gideon M Hirschfield; Cynthia Levy; John Vierling; David Jones; Anne Tailleux; Bart Staels; Sophie Megnien; Remy Hanf; David Magrez; Pascal Birman; Velimir Luketic
Journal:  J Hepatol       Date:  2021-01-21       Impact factor: 25.083
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.